AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Inflammatory bowel disease (IBD) is inflammatory intestinal disorders associated with dysregulated gut microbiota. Bacteriotherapy that leverages bacteria as therapeutics has shown tremendous promise in resolving gut dysbiosis and reducing inflammatory mediators to treat IBD. Orally delivered probiotics, such as Escherichia coli Nissle 1917 (EcN), can produce beneficial ingredients, competitively inhibit the proliferation of pathogens, and promote the restoration of gut microbiome homeostasis. However, environmental stresses (such as gastric acids) in the gastrointestinal (GI) tract pose an enormous challenge to the probiotics following oral administration, leading to decreases in viability and activity of probiotics. Meanwhile, the inferior mucoadhesive capability of probiotics results in low colonization efficacy, further compromising their therapeutic effect. Coating probiotics with functional biomaterials may protect them from elimination and prolong their retention in the GI tract. Here, we developed a facile double-layer electrostatic assembly technique to encapsulate EcN bacteria in protective layers of mucoadhesive chitosan (CS) and immunomodulatory hyaluronic acid (HA) to generate HA-CS-EcN. These biomaterials confer the coated EcN resistance to environmental assault and enhanced mucoadhesion in the GI tract. The probiotics equipped with the multifunctional shield can thus suppress inflammation and reshape the intestinal microenvironment to enhance therapeutic efficacy for the prevention and treatment of IBD. Collectively, this study presents a novel probiotic coating strategy to augment the outcome of bacteriotherapy to combat IBD.
Jairath, V.; Feagan, B. G. Global burden of inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 2020, 5, 2–3.
Xu, F.; Dahlhamer, J. M.; Zammitti, E. P.; Wheaton, A. G.; Croft, J. B. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease—United States, 2015 and 2016. MMWR Morb. Mortal. Wkly. Rep. 2018, 67, 190–195.
Terlizzi, E. P.; Dahlhamer, J. M.; Xu, F.; Wheaton, A. G.; Greenlund, K. J. Health care utilization among U.S. adults with inflammatory bowel disease, 2015–2016. Natl. Health Stat. Rep. 2021, 1–7.
Kaplan, G. G.; Ng, S. C. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017, 152, 313–321.e2.
Lasry, A.; Zinger, A.; Ben-Neriah, Y. Inflammatory networks underlying colorectal cancer. Nat. Immunol. 2016, 17, 230–240.
Danese, S.; Solitano, V.; Jairath, V.; Peyrin-Biroulet, L. The future of drug development for inflammatory bowel disease: The need to ACT (advanced combination treatment). Gut 2022, 71, 2380–2387.
Johnson, F. R.; Özdemir, S.; Mansfield, C.; Hass, S.; Miller, D. W.; Siegel, C. A.; Sands, B. E. Crohn’s disease patients’ risk-benefit preferences: Serious adverse event risks versus treatment efficacy. Gastroenterology 2007, 133, 769–779.
Liu, J.; Wang, Y. X.; Heelan, W. J.; Chen, Y.; Li, Z. T.; Hu, Q. Y. Mucoadhesive probiotic backpacks with ROS nanoscavengers enhance the bacteriotherapy for inflammatory bowel diseases. Sci. Adv. 2022, 8, eabp8798.
Li, J. W.; Sun, M. C.; Liu, L. L.; Yang, W. G.; Sun, A.; Yu, J. C.; Liu, D. C.; Zhao, W. T.; Cheng, M. S.; He, Z. G. et al. Nanoprobiotics for remolding the pro-inflammatory microenvironment and microbiome in the treatment of colitis. Nano Lett. 2023, 23, 8593–8601.
Bäumler, A. J.; Sperandio, V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016, 535, 85–93.
Caruso, R.; Lo, B. C.; Núñez, G. Host–microbiota interactions in inflammatory bowel disease. Nat. Rev. Immunol. 2020, 20, 411–426.
Tan, J.; McKenzie, C.; Potamitis, M.; Thorburn, A. N.; Mackay, C. R.; Macia, L. The role of short-chain fatty acids in health and disease. Adv. Immunol. 2014, 121, 91–119.
Venegas, D. P.; De la Fuente, M. K.; Landskron, G.; González, M. J.; Quera, R.; Dijkstra, G.; Harmsen, H. J. M.; Faber, K. N.; Hermoso, M. A. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol. 2019, 10, 277.
Ashraf, M. F.; Tageldin, O.; Nassar, Y.; Batool, A. Fecal microbiota transplantation in patients with recurrent Clostridium difficile infection: A four-year single-center retrospective review. Gastroenterol. Res. 2021, 14, 237–243.
Schroeder, B. O.; Bäckhed, F. Signals from the gut microbiota to distant organs in physiology and disease. Nat. Med. 2016, 22, 1079–1089.
Bjarnason, I.; Sission, G.; Hayee, B. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology 2019, 27, 465–473.
Xu, J. Q.; Xu, J. C.; Shi, T. F.; Zhang, Y. L.; Chen, F. M.; Yang, C.; Guo, X. J.; Liu, G. N.; Shao, D.; Leong, K. W. et al. Probiotic-inspired nanomedicine restores intestinal homeostasis in colitis by regulating redox balance, immune responses, and the gut microbiome. Adv. Mater. 2023, 35, 2207890.
Zhao, Z. J.; Xu, S. M.; Zhang, W. Y.; Wu, D. J.; Yang, G. S. Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications. Food Funct. 2022, 13, 5914–5924.
Cao, Z. P.; Wang, X. Y.; Pang, Y.; Cheng, S. S.; Liu, J. Y. Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment. Nat. Commun. 2019, 10, 5783.
Liu, J.; Yuan, S. C.; Bremmer, A.; Hu, Q. Y. Convergence of nanotechnology and bacteriotherapy for biomedical applications. Adv. Sci. 2024, 11, 2309295.
Liu, J.; Li, W.; Wang, Y. X.; Ding, Y. Y.; Lee, A.; Hu, Q. Y. Biomaterials coating for on-demand bacteria delivery: Selective release, adhesion, and detachment. Nano Today 2021, 41, 101291.
Wang, X. Y.; Cao, Z. P.; Zhang, M. M.; Meng, L.; Ming, Z. Z.; Liu, J. Y. Bioinspired oral delivery of gut microbiota by self-coating with biofilms. Sci. Adv. 2020, 6, eabb1952.
Bayer, I. S. Recent advances in mucoadhesive interface materials, mucoadhesion characterization, and technologies. Adv. Mater. Interfaces 2022, 9, 2200211.
Knopf-Marques, H.; Pravda, M.; Wolfova, L.; Velebny, V.; Schaaf, P.; Vrana, N. E.; Lavalle, P. Hyaluronic acid and its derivatives in coating and delivery systems: Applications in tissue engineering, regenerative medicine and immunomodulation. Adv. Healthc. Mater. 2016, 5, 2841–2855.
Xu, J. Q.; Chu, T. J.; Yu, T. T.; Li, N. S.; Wang, C. L.; Li, C.; Zhang, Y. L.; Meng, H.; Nie, G. J. Design of diselenide-bridged hyaluronic acid nano-antioxidant for efficient ROS scavenging to relieve colitis. ACS Nano 2022, 16, 13037–13048.
Zhang, J. X.; Zhao, Y. G.; Hou, T. L.; Zeng, H. R.; Kalambhe, D.; Wang, B.; Shen, X. Y.; Huang, Y. Z. Macrophage-based nanotherapeutic strategies in ulcerative colitis. J. Control. Release 2020, 320, 363–380.
Praveschotinunt, P.; Duraj-Thatte, A. M.; Gelfat, I.; Bahl, F.; Chou, D. B.; Joshi, N. S. Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut. Nat. Commun. 2019, 10, 5580.
Cremers, C. M.; Knoefler, D.; Vitvitsky, V.; Banerjee, R.; Jakob, U. Bile salts act as effective protein-unfolding agents and instigators of disulfide stress in vivo. Proc. Natl. Acad. Sci. USA 2014, 111, E1610–E1619.
Lee, Y.; Sugihara, K.; Gillilland III, M. G.; Jon, S.; Kamada, N.; Moon, J. J. Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat. Mater. 2020, 19, 118–126.
